Mineralys Therapeutics (NASDAQ:MLYS) Releases Earnings Results, Beats Estimates By $0.04 EPS

Mineralys Therapeutics (NASDAQ:MLYS) posted its quarterly earnings data on Wednesday. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.04, FiscalAI reports.

Here are the key takeaways from Mineralys Therapeutics’ conference call:

• The FDA accepted the NDA for lorundrostat with a PDUFA target date of December 22, 2026, moving the program meaningfully closer to a potential U.S. launch.
• Mineralys cites a comprehensive data package (Launch?HTN, Advance?HTN, Transform?HTN, Target?HTN, Explore?CKD) showing durable, clinically meaningful blood pressure reductions and a favorable tolerability profile that management believes supports guideline inclusion and payer value arguments.
• The company is actively building commercial capabilities (sales, MSLs, payer engagement) with an initial launch focus on the 4th?line/resistant hypertension population while continuing strategic partner discussions and considering additional development opportunities.
• Mineralys ended Q1 with $646.1M in cash and investments—positioning the company to fund operations into 2028—but reported higher G&A as it scales commercial readiness and a Q1 net loss of $39.3M.

Mineralys Therapeutics Price Performance

NASDAQ MLYS traded up $0.84 on Wednesday, reaching $30.12. The stock had a trading volume of 1,002,965 shares, compared to its average volume of 1,063,670. The firm has a fifty day moving average of $27.16 and a two-hundred day moving average of $33.24. Mineralys Therapeutics has a 1-year low of $12.59 and a 1-year high of $47.65. The company has a market cap of $2.48 billion, a P/E ratio of -12.71 and a beta of 0.49.

Insider Transactions at Mineralys Therapeutics

In other Mineralys Therapeutics news, CEO Jon Congleton sold 75,000 shares of Mineralys Therapeutics stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $26.27, for a total value of $1,970,250.00. Following the completion of the transaction, the chief executive officer directly owned 705,051 shares of the company’s stock, valued at $18,521,689.77. The trade was a 9.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daphne Karydas sold 3,000 shares of Mineralys Therapeutics stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $25.00, for a total value of $75,000.00. Following the completion of the transaction, the director directly owned 6,200 shares of the company’s stock, valued at $155,000. This represents a 32.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 162,291 shares of company stock valued at $4,336,414. Corporate insiders own 18.94% of the company’s stock.

Hedge Funds Weigh In On Mineralys Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc raised its holdings in Mineralys Therapeutics by 1,296.2% in the 2nd quarter. Legal & General Group Plc now owns 36,049 shares of the company’s stock valued at $488,000 after acquiring an additional 33,467 shares in the last quarter. Police & Firemen s Retirement System of New Jersey raised its holdings in Mineralys Therapeutics by 15.7% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 12,683 shares of the company’s stock valued at $460,000 after acquiring an additional 1,717 shares in the last quarter. FORA Capital LLC raised its holdings in shares of Mineralys Therapeutics by 74.7% during the 4th quarter. FORA Capital LLC now owns 11,050 shares of the company’s stock worth $401,000 after buying an additional 4,725 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Mineralys Therapeutics by 219.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 25,500 shares of the company’s stock worth $345,000 after buying an additional 46,846 shares in the last quarter. Finally, Man Group plc raised its holdings in shares of Mineralys Therapeutics by 50.1% during the 2nd quarter. Man Group plc now owns 21,852 shares of the company’s stock worth $296,000 after buying an additional 7,293 shares in the last quarter. 84.46% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently issued reports on MLYS. Wall Street Zen upgraded Mineralys Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Tuesday, April 21st. Jefferies Financial Group reiterated a “hold” rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a report on Friday, March 13th. HC Wainwright set a $56.00 price target on Mineralys Therapeutics and gave the company a “buy” rating in a research note on Tuesday, March 10th. Finally, TD Cowen initiated coverage on Mineralys Therapeutics in a research note on Monday, April 27th. They issued a “buy” rating for the company. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Mineralys Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $49.14.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.